Please login to the form below

Not currently logged in
Email:
Password:

Pixuvri

This page shows the latest Pixuvri news and features for those working in and with pharma, biotech and healthcare.

Servier begins construction of new R&D hub in Paris

Servier begins construction of new R&D hub in Paris

The company was hit last year when the much-anticipated Pixuvri failed in a phase 3 trial for in non-Hodgkin’s lymphoma (NHL).

Latest news

  • CTI slumps as Servier-partnered lymphoma drug fails CTI slumps as Servier-partnered lymphoma drug fails

    CTI BioPharma has been poleaxed by the news that its much-anticipated late-stage trial for Pixuvri in non-Hodgkin’s lymphoma (NHL) has ended in failure. ... The PIX306 trial paired Pixuvri (pixantrone) – already sold in some European markets as a

  • CTI launches cancer drug Pixuvri in UK CTI launches cancer drug Pixuvri in UK

    Now available to treat form of non-Hodgkin lymphoma. Cell Therapeutics Inc (CTI) has launched its cancer treatment Pixuvri in the UK. ... were later resolved at the end of 2013, meaning Pixuvri is available for reimbursement.

  • NICE relents and gives Pixuvri limited backing NICE relents and gives Pixuvri limited backing

    Recommends Cell Therapeutics drug for an aggressive form of cancer. Cell Therapeutics has scraped a limited recommendation from NICE for its non-Hodgkin's lymphoma drug Pixuvri. ... Cell Therapeutics' first drug on the market, Pixuvri was recommended by

  • NICE unmoved by Pixuvri access scheme NICE unmoved by Pixuvri access scheme

    Cell Therapeutics now has another consultation period in which it can try and convince NICE to recommend Pixuvri. ... The NICE guidance is the latest hurdle for Cell Therapeutics in a series of challenges related to Pixuvri – the company's first drug

  • Roche wins conditional EU approval for cancer drug Erivedge Roche wins conditional EU approval for cancer drug Erivedge

    Cell Therapeutics' Pixuvri (pixantrone) for non-Hodgkin B-cell lymphoma.

More from news
Approximately 5 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial ... This exclusion of trial data from other

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics